文献速递外周动脉疾病

2型糖尿病合并下肢动脉疾病患者主要局部下肢事件的发生:二甲双胍的影响

Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin.
PubMed 文献 · Ann Vasc Surg · 2022-10-28

前瞻性研究纳入100例2型糖尿病合并下肢动脉疾病患者,随访12个月,37%发生主要不良肢体事件(MALE)。多变量分析显示二甲双胍与MALE风险降低相关(OR=0.26,95%CI 0.10-0.68,P=0.007),静脉伊洛前列素治疗史与MALE风险升高相关(OR=5.70,95%CI 1.31-31.93,P=0.029)。作者结论认为二甲双胍对糖尿病患者下肢动脉疾病的局部并发症具有保护作用,应早期处方。

要点

  • 100例2型糖尿病合并下肢动脉疾病患者随访12个月,37%发生MALE。
  • 二甲双胍与MALE风险降低相关(OR=0.26,95%CI 0.10-0.68,P=0.007)。
  • 静脉伊洛前列素治疗史与MALE风险升高相关(OR=5.70,95%CI 1.31-31.93,P=0.029)。

核心结论

  • 二甲双胍对糖尿病合并下肢动脉疾病患者的局部并发症具有保护作用,应早期处方于糖尿病合并下肢动脉疾病患者。

研究设计与样本

  • 前瞻性研究,纳入2017年11月至2018年5月期间的2型糖尿病合并下肢动脉疾病患者,随访12个月,共100例。

主要发现

  • 37%的患者发生MALE;多变量分析显示二甲双胍与MALE风险降低相关(OR=0.26,95%CI 0.10-0.68,P=0.007),静脉伊洛前列素治疗史与MALE风险升高相关(OR=5.70,95%CI 1.31-31.93,P=0.029)。
  • 规律体力活动与MACE风险降低相关(OR=0.07,95%CI 0-0.44,P=0.021)。
  • 卒中史与全因死亡风险升高相关(OR=3.68,95%CI 1.17-11.5,P=0.025),静脉血栓栓塞史与全因死亡风险升高相关(OR=3.78,95%CI 1.16-12.3,P=0.027)。

临床怎么用

  • 作者认为二甲双胍对糖尿病合并下肢动脉疾病患者的局部并发症具有保护作用,应早期处方于糖尿病合并下肢动脉疾病患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDS: Patients with type 2 diabetes mellitus (T2DM) are particularly at risk of developing major adverse cardiovascular events (MACE) and peripheral artery disease (PAD) due to an acceleration of the atherosclerotic process linked to hyperglycemia and inflammation with a greater risk of local complications. We aimed to identify the predictive factors for major adverse limb events (MALE) in T2DM patients with PAD to manage modifiable factors at an early stage. METHODS: This is a prospective study in which T2DM patients with PAD were included from November 2017 to May 2018 and followed over 12 months. The predictive factors for the onset of MALE, MACE, and death from all causes have been identified. RESULTS: A total of 100 patients were included; 37% of the patients developed a MALE. After multivariate analysis, metformin was associated with a decrease of MALE (odds ratio (OR) = 0.26; 95% confidence interval (CI) [0.10; 0.68]; P = 0.007), and a history of the treatment of intravenous iloprost was associated with an increased risk of MALE (OR = 5.70; 95% CI [1.31; 31.93]; P = 0.029). Regular physical activity was associated with a decreased risk of MACE (OR = 0.07; 95% CI [0; 0.44]; P = 0.021). A history of stroke and a history of venous thromboembolism were associated with an increased all-cause mortality risk with OR = 3.68; 95% CI [1.17; 11.5]; P = 0.025 and OR = 3.78; 95% CI [1.16; 12.3]; P = 0.027. CONCLUSIONS: Metformin is protective against local complications in people with diabetes with PAD and should be prescribed to diabetic patients with PAD at an early stage.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tan S, Goudot G, Arnoux A, et al. Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin. Ann Vasc Surg. 2022. PMID: 36441097. doi:10.1016/j.avsg.2022.09.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。